Regulatory News:

ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today its financial agenda for the 1st half of 2024.



2023 Full-Year Results

April 30th 2024

Annual General Meeting

June 21th 2024

* Information subject to change.


Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), which is aiming to develop an innovative treatment for cardiovascular emergencies, including ischemic stroke.

The positive results of the phase 1b/2a study, ACTIMIS, confirmed the safety profile of glenzocimab and showed a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group of stroke patients. These results were confirmed by a post-hoc analysis of brain imaging at 0 and 24 hours using artificial intelligence (Brainomix, UK). This independent analysis confirmed the reduction in the number and volume of intracerebral lesions in patients treated with glenzocimab. The efficacy of glenzocimab is now being analyzed in an international Phase 2/3 study, ACTISAVE, with clinical results expected in Q2 2024.

In July 2022, Acticor Biotech was granted "PRIME" status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke. This designation will allow the company to strengthen its interactions and obtain early dialogues with regulatory authorities.

Acticor Biotech is supported by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 – ALACT).

For more information, visit:

ACTICOR BIOTECH Gilles AVENARD, MD Directeur Général et fondateur T. : +33 (0)6 76 23 38 13

Sophie BINAY, PhD Directeur Général Délégué et Directeur Scientifique T. : +33 (0)6 76 23 38 13

NewCap Mathilde BOHIN Relations Investisseurs T. : +33 (0)1 44 71 94 95

NewCap Arthur ROUILLÉ Relations Médias T. : +33 (0)1 44 71 00 15

Acticor Biotech (EU:ALACT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Acticor Biotech Charts.
Acticor Biotech (EU:ALACT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Acticor Biotech Charts.